Lifecore Biomedical, Inc. LFCR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s additional paid-in capital?
- Lifecore Biomedical, Inc. (LFCR) reported additional paid-in capital of $209.71M in Q1 2026.
- How has Lifecore Biomedical, Inc.'s additional paid-in capital changed year-over-year?
- Lifecore Biomedical, Inc.'s additional paid-in capital increased by 1.5% year-over-year, from $206.54M to $209.71M.
- What is the long-term trend for Lifecore Biomedical, Inc.'s additional paid-in capital?
- Over 5 years (2021 to 2026), Lifecore Biomedical, Inc.'s additional paid-in capital has grown at a 4.8% compound annual growth rate (CAGR), from $165.53M to $209.71M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.